A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

被引：0
|
作者：
Jian Hou
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Huisheng Ai
Jingshan Zhang
Honeylet Wortman-Vayn
Nianhang Chen
Jay Mei
Jianmin Wang
机构：
[1] Shanghai Changzheng Hospital,Department of Hematology
[2] Guangdong General Hospital,The 1st Hospital
[3] Zhejiang University,undefined
[4] Xiangya Hospital of Central South University,undefined
[5] Peking Union Medical College Hospital,undefined
[6] The 301 Hospital-Chinese PLA General Hospital,undefined
[7] Peking University Third Hospital,undefined
[8] Shanghai 6th Hospital,undefined
[9] The 1st Affiliated Hospital of Soochow University,undefined
[10] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[11] The 307 PLA Hospital,undefined
[12] Celgene Corporation,undefined
[13] Changhai Hospital,undefined
来源：
Journal of Hematology & Oncology | / 6卷
关键词：
Relapsed/Refractory Multiple Myeloma; Chinese Patients; Lenalidomide; Low-dose Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study
    Pozzi, Samantha
    Gentile, Massimo
    Sacchi, Stefano
    Marcheselli, Raffaella
    Corso, Alessandro
    Cocito, Federica
    Musto, Pellegrino
    Guarini, Attilio
    Minoia, Carla
    Vincelli, Iolanda
    Ria, Roberto
    Rivolti, Elena
    Mele, Giuseppe
    Bari, Alessia
    Mazzone, Carla
    Badiali, Stefania
    Marcheselli, Luigi
    Palumbo, Antonio
    Morabito, Fortunato
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 552 - 559
  • [42] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [43] Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
    Suzuki, Kenshi
    Shinagawa, Atsushi
    Uchida, Toshiki
    Taniwaki, Masafumi
    Hirata, Hirokazu
    Ishizawa, Kenichi
    Matsue, Kosei
    Ogawa, Yoshiaki
    Shimizu, Takayuki
    Otsuka, Maki
    Matsumoto, Morio
    Iida, Shinsuke
    Terui, Yasuhito
    Matsumura, Itaru
    Ikeda, Takashi
    Takezako, Naoki
    Ogaki, Yumi
    Midorikawa, Shuichi
    Houck, Vanessa
    Ervin-Haynes, Annette
    Chou, Takaaki
    CANCER SCIENCE, 2016, 107 (05) : 653 - 658
  • [44] Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
    Lonial, Sagar
    Popat, Rakesh
    Hulin, Cyrille
    Jagannath, Sundar
    Oriol, Albert
    Richardson, Paul G.
    Facon, Thierry
    Weisel, Katja
    Larsen, Jeremy T.
    Minnema, Monique C.
    Abdallah, Al-Ola
    Badros, Ashraf Z.
    Knop, Stefan
    Stadtmauer, Edward A.
    Cheng, Yiming
    Amatangelo, Michael
    Chen, Min
    Tuong Vi Nguyen
    Amin, Alpesh
    Peluso, Teresa
    van de Donk, Niels W. C. J.
    LANCET HAEMATOLOGY, 2022, 9 (11): : E822 - E832
  • [45] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    Berenson, J. R.
    Yellin, O.
    Kazamel, T.
    Hilger, J. D.
    Chen, C-S
    Cartmell, A.
    Woliver, T.
    Flam, M.
    Bravin, E.
    Nassir, Y.
    Vescio, R.
    Swift, R. A.
    LEUKEMIA, 2012, 26 (07) : 1675 - 1680
  • [46] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    J R Berenson
    O Yellin
    T Kazamel
    J D Hilger
    C-S Chen
    A Cartmell
    T Woliver
    M Flam
    E Bravin
    Y Nassir
    R Vescio
    R A Swift
    Leukemia, 2012, 26 : 1675 - 1680
  • [47] Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
    Del Giudice, Maria Livia
    Gozzetti, Alessandro
    Antonioli, Elisabetta
    Orciuolo, Enrico
    Ghio, Francesco
    Ciofini, Sara
    Candi, Veronica
    Fontanelli, Giulia
    Attucci, Irene
    Formica, Giuseppe
    Bocchia, Monica
    Galimberti, Sara
    Petrini, Mario
    Buda, Gabriele
    MEDICINA-LITHUANIA, 2021, 57 (09):
  • [48] A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results
    Spencer, Andrew
    Harrison, Simon
    Zonder, Jeffrey
    Badros, Ashraf
    Laubach, Jacob
    Bergin, Krystal
    Khot, Amit
    Zimmerman, Todd
    Chauhan, Dharminder
    Levin, Nancy
    MacLaren, Ann
    Reich, Steven D.
    Trikha, Mohit
    Richardson, Paul
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 41 - 51
  • [49] Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
    Mateos, Maria-Victoria
    Granell, Miguel
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Blade, Joan
    Hernandez, Miguel T.
    Martin, Jesus
    Gironella, Mercedes
    Lynch, Mark
    Bleickardt, Eric
    Paliwal, Prashni
    Singhal, Anil
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 448 - 456
  • [50] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
12345